Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2020-12-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
第二期员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of an employee stock ownership plan (员工持股计划) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes comprehensive information about the plan's principles, participants, funding sources, stock sources, pricing, duration, lock-up periods, performance assessments, management, and procedural steps. The document references relevant laws and regulations and outlines the governance and operational details of the employee stock ownership plan. It is not a financial report like an annual or quarterly report, nor is it an announcement of voting results or a proxy statement. It is a detailed plan document related to capital structure and employee equity participation. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through an employee stock ownership plan.
2020-12-28 Chinese
关于子公司完成工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the completion of industrial and commercial registration changes for its subsidiaries after a board resolution to increase capital and adjust shareholdings. It details the updated registration information of the subsidiaries, including company names, types, registered capital, legal representatives, and business scope. The document is relatively short (2165 characters) and serves as a formal public notice of corporate structural changes rather than a financial report or detailed management discussion. There is no financial statement, audit information, or detailed financial analysis. It is not a report itself but an announcement of a corporate event related to capital and shareholding changes. Therefore, the best fitting category is Capital/Financing Update (CAP).
2020-12-28 Chinese
董事会关于公司第二期员工持股计划（草案）符合《关于上市公司实施员工持股计划试点的指导意见》等规定的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors of Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the compliance of the company's second employee stock ownership plan (ESOP) with relevant laws, regulations, and guidelines. It explains the legality, procedural correctness, and benefits of the ESOP but does not contain financial statements or detailed financial data. The document is relatively short (896 characters) and serves as an announcement or explanation rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update. It is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance disclosure related to employee stock plans without substantive financial data or report content.
2020-12-28 Chinese
独立董事关于公司有关事项所发表的独立意见
Transaction in Own Shares Classification · 95% confidence The document is a formal independent directors' opinion on company matters, specifically regarding the adjustment of the company's share repurchase (buyback) purpose and the company's second employee stock ownership plan. It references compliance with various laws and regulations, and confirms the legality and appropriateness of these corporate actions. The document does not contain financial statements or detailed financial data but rather provides an independent opinion on corporate governance and specific corporate actions. This type of document is typically classified under 'Transaction in Own Shares' (POS) when it relates to share repurchase plans and their adjustments, especially since it discusses the adjustment of the repurchase purpose. The document length is short (1455 characters), and it is not an announcement of a report publication but an independent opinion letter. Therefore, the best fitting category is POS (Transaction in Own Shares).
2020-12-28 Chinese
第五届监事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the Supervisory Board meeting of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses approval of adjustments to the company's share repurchase plan and an employee stock ownership plan draft. The document is a formal meeting resolution announcement, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is short (1645 characters), and it serves as a formal disclosure of board decisions. This fits best with the category of Regulatory Filings (RNS), which is the fallback for announcements that do not fit other specific categories such as management changes, earnings releases, or capital updates.
2020-12-28 Chinese
第二期员工持股计划管理办法
Governance Information Classification · 95% confidence The document is titled as the "Second Employee Stock Ownership Plan Management Measures" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the rules, rights, obligations, management structure, voting procedures, lock-up periods, performance assessments, and other governance aspects of the employee stock ownership plan. It references relevant laws and regulatory guidelines related to employee stock ownership plans. The document is a detailed internal governance and management framework for the employee stock ownership plan rather than a financial report, announcement, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a proxy solicitation. It is a governance document outlining the internal rules and structure of the employee stock ownership plan. Therefore, the most appropriate classification is Governance Information (CGR).
2020-12-28 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.